ARMP
AMEX · Biotechnology
Armata Pharmaceuticals Inc
$7.70
-0.38 (-4.70%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 50.93M | 51.72M | 48.38M |
| Net Income | -16,386,219 | -16,237,176 | -12,069,043 |
| EPS | — | — | — |
| Profit Margin | -32.2% | -31.4% | -24.9% |
| Rev Growth | +4.2% | -2.8% | -3.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 120.62M | 107.00M | 137.33M |
| Total Equity | 97.05M | 94.95M | 97.16M |
| D/E Ratio | 1.24 | 1.13 | 1.41 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -22,680,337 | -19,844,642 | -21,697,061 |
| Free Cash Flow | -12,782,246 | -12,228,215 | -11,985,347 |